Clinical Trial

Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The Investigators plan to conduct a long-term trial to explore therapeutic implications of effervescent calcium magnesium citrate (EffCaMgCit) in CKD Stage V (end stage renal disease on hemodialysis). The Investigators will test the hypothesis that EffCaMgCit would retard the formation of calciprotein particles (CPP) in CKD Stage V, thereby reducing the degree of coronary artery and peripheral artery calcification and cardiac hypertrophy-fibrosis. Aim 1. To compare cardiovascular risk of EffCaMgCit versus CaAcS in CKD Stage V Aim 2. To show that EffCaMgCit reduces putative serum FGF23, and increases beneficial alkali load Aim 3. To compare parameters of bone turnover and bone mineral density (BMD) between EffCaMgCit and CaAcS groups
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-06-11; most recent amendment 2026-06-01.
Status change: Recruiting → Active, Not Recruiting 2024-11-05
Status change: Active, Not Recruiting → Recruiting 2023-10-11
Status change: Recruiting → Active, Not Recruiting 2023-01-20
Status change: Active, Not Recruiting → Recruiting 2022-02-09
Status change: Recruiting → Active, Not Recruiting 2020-05-11
Trial Details
NCT Number NCT03565913
Lead Sponsor University of Texas Southwestern Medical Center
Conditions CKD Stage 5
Enrollment 269 participants
Start Date 2017-01-22
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-06-03